A novel, non-opioid, ocular pain compound
DENKI can enhance the power of enkephalins, a key element of the body’s natural pain modulation system, by protecting them from degradation and allowing them to locally increase in concentration. Corneal tissues contain all the elements of the enkephalinergic system which allows DENKI to maximize their effect. This means more relief with less side effects.
IPAC will lead the clinical and commercial development of the world’s first non-opioid drug harnessing endogenous analgesia for the treatment of chronic and acute ocular pain. Analgesic effects were demonstrated in all of our ocular pain and dry eye disease animal models tests.
Based on research and development efforts, DENKI has the potential to be positioned as an ocular analgesia that can also protect the corneal epithelium.